行情

BCLI

BCLI

Brainstorm Cell
NASDAQ

实时行情|Nasdaq Last Sale

3.710
-0.040
-1.07%
已收盘, 16:00 11/18 EST
开盘
3.700
昨收
3.750
最高
3.740
最低
3.650
成交量
4.11万
成交额
--
52周最高
4.500
52周最低
2.920
市值
8,387.01万
市盈率(TTM)
-4.2193
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BCLI 新闻

  • 沪指低开高走 鲍威尔同特朗普及美财长会晤
  • 新浪财经.27分钟前
  • 泰国推“减塑”政策 商场超市等明年起不提供塑料袋
  • 中国新闻网.3小时前
  • 苹果“泰坦计划”又获新专利 可进行自动驾驶导航
  • 36氪.4小时前
  • 特朗普再次召见美联储主席讨论经济问题
  • 新华社.4小时前

更多

所属板块

生物技术和医学研究
+0.31%
制药与医学研究
+0.13%

热门股票

名称
价格
涨跌幅

BCLI 简况

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
展开

Webull提供Brainstorm Cell Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。